Background
The hallmark of Amyotrophic Lateral Sclerosis (ALS) is the selective death of upper and lower motor neurons in the motor cortex, brainstem and spinal cord, leading to loss of voluntary muscle control, muscle atrophy and invariably death. The specific causes of most cases of ALS are undefined, although approximately 10 % are inherited. The best-studied familial ALS (fALS) cases are from families possessing mutations in the gene encoding copper/zinc superoxide dismutase (Cu/Zn SOD,
SOD1) [
1]. There is, however, a rapidly growing list of other genes in which mutations have been implicated in fALS. These include
ALS2,
SETX,
FUS,
VAPB,
ANG,
TARDBP,
OPTN,
VCP,
UBQLN2,
PFN1, SQSTM1, and a hexanucleotide repeat in a non-coding region of
C9ORF72 [
2]. Current clinical practices are such that by the time that a diagnosis is confirmed disease progression is well under way and as many as 50 % of motor units may already have been affected [
3]. There is now very strong evidence in humans that neurodegeneration in ALS begins focally and then spreads amongst adjacent motor neurons or through axonal pathways throughout the three dimensional anatomy of the central nervous system [
4‐
6]. More detailed knowledge of the action of this spreading is crucial, as is identifying a means of early detection of the disease if we are to therapeutically slow disease progression.
In common with other neurodegenerative diseases, such as Alzheimer’s Disease and Parkinson’s Disease [
7,
8], there is growing evidence that disruptions to proteostasis, protein misfolding and aggregation are the underlying mechanisms driving neurodegeneration in ALS [
9]. Of particular interest is the fact that, although nucleation of protein aggregation appears to be a stochastic process [
10], suggesting that protein aggregation should cause a random pattern of cell death, cell death in ALS occurs in an ordered and progressive manner. One way to explain such ordered progression is the prion-like propagation of protein misfolding and aggregation between adjacent cells. In addition, recent work has indicated that secondary processes, notably nucleation [
11‐
13], takes place on the surface of aggregates, and along with other diffusional or active transport of protein aggregates between cells can give rise to cell-to-cell propagation of the type that is often defined as prion-like behaviour.
In the specific context of ALS, previous work has shown that exogenously applied mutant SOD1 aggregates induce protein aggregation in cells overexpressing mutant SOD1 [
14]. Importantly, recent work shows that injection of spinal cord homogenates from symptomatic G93A SOD1 mice into the sciatic nerve of mice expressing G85R SOD1-YFP, below the threshold for triggering disease, has been shown to kindle protein aggregation and subsequent ALS-like phenotype [
15]. In addition, we have recently shown, using cell lines and primary neurons, that propagation of SOD1 misfolding is dependent upon the passage of misfolded SOD1 (either mutant or wt) from cell-to-cell, a process that can be neutralized by antibodies reactive with misfolded SOD1 epitopes [
16]. We have also shown that soluble and aggregated SOD1 can be taken up by neuroblastoma cells (mouse NSC-34 and human SHSY5Y), after which it accumulates in cytosolic inclusions [
17]. Clues to understanding the entry of aggregates into cells comes from studies that show uptake of aggregates of SOD1 can be blocked with EIPA, wortmannin, IPA-3 [
14] and rottlerin [
16,
17], which inhibit Na
+/H
+ exchangers, phosphoinositide 3-kinases (PI3K), P21 protein (Cdc42/Rac)-activated kinase 1 (PAK-1) and protein kinase C (PKC), respectively (suppressing signalling events that promote actin rearrangement and pinosome closure). These findings suggest the involvement of fluid phase pinocytosis, possibly macropinocytosis, in the aggregate uptake process. Similarly, we have shown that cellular uptake of soluble SOD1 can be blocked by co-treatment with EIPA or rottlerin also suggesting that a form of pinocytosis plays a role in this process [
17].
Macropinocytosis is a form of non-selective endocytosis used by cells to engulf large amounts of solute macromolecules (fluid phase) or particles too large for other forms of endocytosis. Macropinocytosis is typically defined as a transient, externally induced, actin-dependent endocytic process associated with vigorous perturbations, such as ruffles and blebs, in the plasma membrane [
18]. The activation of this process results in a transient increase in receptor-independent fluid phase endocytosis in large vesicles or vacuoles (0.5–10 μm) termed macropinosomes [
18,
19]. Macropinosomes do not have a coat to guide their formation and are heterogeneous in size and shape. Macropinocytosis provides non-phagocytic cells with the ability to take up large particles, but the process must be triggered by an external stimulus. Bacteria, viruses, apoptotic bodies and necrotic cells have all been shown to induce the ruffling behaviour typical of macropinocytosis resulting in their uptake along with fluid [
18].
There are a number of viruses, including the vaccinia virus and adenovirus [
20], that have been shown to hijack macropinocytosis pathways to enter cells, including the Japanese encephalitis virus that triggers macropinocytosis in neurons [
21]. A lack of physical structure is thought to result in the loss of integrity of the macropinosome membrane and may explain why particles (e.g. bacteria and virions) can escape the macropinosomes and reach the cytosol [
22]. There is emerging evidence that prions and prion-like proteins may also enter cells via macropinocytosis allowing the propagation of their aggregation [
14,
16,
17,
23,
24]. However, the small molecule inhibitors utilized to define macropinocytosis, such as EIPA, are not specific to a single cellular event and depending on the cell type can prevent various forms of endocytosis [
25].
We show here however, that aggregates of SOD1 trigger activation of the Rho GTPase Rac1, leading to membrane ruffling and fluid phase uptake in neurons that defines macropinocytosis and that this facilitates aggregate entry into cells. In addition, we show that these aggregates can escape macropinosomes to be deposited in the cytosol. We further show that this process is not specific for SOD1 but rather can be triggered by a variety of protein aggregates, including model protein aggregates (α-lactalbumin) and those associated with neurodegenerative diseases (TDP-43, Httex146Q and α-synuclein). We conclude that the infectious prion-like spread of protein aggregation in a range of neurodegenerative diseases is dependent on cells activating ruffling and subsequent macropinocytosis in a manner analogous to viral entry and propagation through activation of macropinocytosis.
Discussion
The work presented here reveals that both soluble and aggregated SOD1 are taken up by neuronal cells via fluid phase endocytosis pathways. In addition we show that aggregated but not soluble SOD1 triggers activation of Rac1 and subsequent membrane ruffling, and thus itself stimulates macropinocytosis, not only in cell lines but also in human iPSC derived motor neurons. This process differs from that responsible for the uptake of soluble SOD1, which is independent of membrane ruffling and occurs presumably via a constitutive form of pinocytosis in the case of the wtSOD1 and potentially via a range of mechanisms in the case of soluble G93A SOD1. SOD1 aggregates are not permanently maintained in a membrane bound compartment once inside the cells, but rupture macropinosomes and escape into the cytosol where they can induce further aggregation. In addition, the data presented here shows that other protein aggregates, including those of TDP-43, Httex1-46Q, α-synuclein, and α-lactalbumin, can also trigger significant perturbations in the plasma membrane of neurons allowing the uptake of large fibrillar or amorphous protein aggregates.
Various viruses, such as the vaccinia virus, adenovirus 3, herpes simplex virus 1 and HIV, utilize macropinocytosis to gain entry to cells. This phenomenon is likely to be due to the fact that macropinosomes are not restricted in size, enabling even large virions to be internalized, and that many cell types, not just professional phagocytes (such as macrophages), have the ability to activate the macropinocytosis pathways [
18]. Indeed, macropinocytosis can be activated in neurons by interactions with large viral particles [
21]. In the specific context of ALS we show that aggregates formed by SOD1 can activate the same macropinocytosis pathways as those utilized by virions and that this can result in the propagation of aggregation. In addition, we show that aggregates formed from TDP-43, which are also associated with ALS, stimulate ruffling and mediates their subsequent cellular uptake. Previous work has shown that amyloid fibrils can enhance HIV viral infection [
39], it is interesting to speculate that this behaviour could be due to the potent ability of such aggregates to stimulate macropinocytosis.
Our data are consistent with the notion that protein aggregates could be an active part of ALS disease progression, possibly through secondary nucleation [
40], or another prion-like aggregate propagation process. Recent work provides striking evidence that this may indeed drive disease progression as focal injection of spinal cord homogenates from symptomatic G93A SOD1 triggers progressive motor neuron disease in mice expressing G85R SOD1-YFP below the threshold for disease [
15]. Our data however, does not directly demonstrate seeding of aggregation and as such we cannot rule out the possibility that the stress of aggregate uptake induces further aggregation in the absence of seeding. We have also shown that Rac1 and protein kinase C (PKC) pathways are actively involved in aggregate uptake. Interestingly, intracellular mutant SOD1 has been found to interact with and activate Rac1 [
41]. Rac1, a Rho GTPase, has been identified as an important and central player in triggering membrane ruffles associated with virus entry into cells and has been found to do so by activating downstream effectors of actin polymerisation [
42]. In addition, while the precise role of PKC in virus entry is still unclear, its activation with PMA (as used in this study) can induce ruffling and fluid uptake in the absence of ligands that bind the cell surface [
43].
There is a growing wave of evidence that is consistent with the hypothesis that protein aggregates propagate between cells and that this is responsible for the orderly progression of disease pathology seen in some neurological disorders [
44‐
49]. The most startling evidence shows that healthy cells grafted into the brains of people with Parkinson’s disease acquires intracellular inclusions of α-synuclein, known as Lewy bodies [
47]. Evidence suggests that large fibrillar aggregates of a range of proteins (tau, α-synuclein, and expanded polyglutamine repeats) are able to gain access to the cytoplasmic compartment via an incompletely understood mechanism and induce protein aggregation [
44,
45,
48,
49]. We show here that aggregates of proteins associated with ALS, Parkinson’s and Huntington’s disease all trigger both membrane ruffling and fluid uptake; findings indicating the stimulation of macropinocytosis.
While much of the focus on toxic aggregate species has been placed on oligomers, our data adds to work already published that demonstrates large insoluble aggregates can be taken up by cells and subsequently promote propagation of aggregation [
16,
23,
44‐
49]. It has previously been shown that aggregation of α-synuclein can be triggered in an acidic environment and that this, through secondary nucleation, may produce a range of aggregates including toxic oligomers [
40]. Taken together, these data suggest that the propagation of large insoluble aggregates through cellular uptake may be responsible for the perpetual propagation and generation of toxic oligomeric species. This conclusion, together with the knowledge of intracellular pathways that result in macropinosome formation and closure, provide possible therapeutic targets for halting the propagation of aggregation in these disorders. For example, we have previously shown that microglia recognize protein aggregates through CD14, scavenger and toll-like receptors, and hence may use receptor-mediated endocytosis, rather than macropinocytosis, to facilitate the uptake of aggregates and to promote their degradation [
50,
51]. This distinction between microglia and neurons provides a possible approach to specifically block the uptake of aggregates by neurons.
Materials and methods
Cell culture
The mouse neuroblastoma x spinal cord hybrid cell line (NSC-34 cells [
52]) were routinely cultured in DMEM/F12 supplemented with 10 % (v/v) FBS and 2 mM GlutaMAX. Cells were maintained in an incubator at 37 °C under a humidified atmosphere containing 5 % (v/v) CO
2. Human fibroblasts were sourced from non-ALS individuals (female aged 62 and male aged 59 at the time of collection) and reprogrammed into induced pluripotent stem cells using mRNA (Miltenyi). Pluripotency was confirmed by PluriTest and differentiation of the cells [
53]. Karyotyping was carried out in iPSCs, to ensure chromosomal abnormalities were not introduced during reprogramming and culture. Immunocytochemistry confirmed the expression of the pluripotency marker Oct4 (Additional file
9A).
Differentiation of pluripotent stem cells into motor neurons was carried out as in [
54] and one clone from each line was used in experiments. Motor neurons (150,000 cells) were plated onto laminin (20 μg/mL) and fibronectin (10 μg/mL) coated 13 mm coverslips. The timeline summarizes the differentiation stages and the growth factor conditions used during differentiation (Additional file
9B). The morphological changes of each cell line were examined at each stage of the differentiation process (Additional file
9B).
Confirmation of motor neuron phenotype was carried out, including expression analysis by quantitative reverse transcription PCR and immunocytochemistry. The differentiated neurons expressed the motor neuron specific markers SMI32 and islet 1 (Additional file
9C). Immunocytochemistry identified the presence of extended dendrites ~100 μm in length. Quantitative reverse transcription PCR analysis identified the expression of the motor neuron specific gene
MNX1 (that encodes the transcription factor homeobox 9, HB9) [
55].
MNX1 was specifically expressed in motor neurons and
MNX1 was silent in pluripotent stem cells. The cholinergic specific marker acetylcholine esterase (
ACHE that encodes the enzyme responsible for the degradation of the neurotransmitter acetylcholine) was specifically expressed in cholinergic motor neurons. The expression levels for both
MNX1 and
ACHE, were normalized to the housekeeper gene
GAPDH (Additional file
8D).
Application of aggregates to cells
Wt and G93A SOD1 were expressed and purified from
E.coli as previously outlined [
50,
56]. SOD1 aggregation was performed in vitro as previously described [
50]. Briefly, solutions of purified wt or G93A mutant SOD1 protein (1 mg/mL) in PBS were co-incubated with 20 mM dithiothreitol (DTT) and 5 mM ethylenediaminetetraacetic acid (EDTA) for 72 h at 37 °C with shaking; aggregated SOD1 was washed several times to remove DTT and EDTA. NSC-34 cells were cultured in 12 well plates and were transfected with wt or mutant SOD1-GFP using lipofectamine 2000 (following the manufacturer’s instructions). Lipofectamine was removed after 5 h and replaced with 10 % FCS in DMEM. After 24 h the aggregates, or soluble (non-aggregated) wtSOD1 as a control, were added in fresh media to transfected or naïve NSC-34 cells. Cells were incubated for a further 48 h and then imaged. In other experiments, aggregates were added to untransfected NSC-34 cells and incubated for various time periods in the presence or absence of pathway inhibitors before fixation and detection of aggregates (see online methods for details). In some experiments, NSC34 cells were incubated with 20 μg/mL of human wt and mutant SOD1 aggregates for 1 h at 37 °C. Post incubation, cells were washed three times in PBS and incubated with trypsin (0.25 %, Invitrogen) for 5 min to remove surface-bound aggregates. The resulting detached cells were centrifuged at 1100 × g for 5 min, re-plated in media, and allowed to recover for 6 h at 37 °C before fixation for immunocytochemistry.
Aggregation and biotinylation of wt and G93A SOD1 aggregates
SOD1 aggregation was performed in vitro as previously described 50. Aggregated SOD1 was labelled with biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt in DMSO for 2 h at RT. The unconjugated biotin was then separated by centrifugation (21 000 x
g for 30 min) and washed three times with PBS. The purified aggregates were then resuspended in PBS (pH 7.4). A bicinchoninic acid protein assay was performed to determine the amount of protein in solution. Aggregated forms of other proteins were obtained by incubation under conditions previously described, Httex146Q [
57] , TDP-43 [
58], α-synuclein [
59], and α-lactalbumin [
38].
Cell surface binding and internalization of aggregated SOD1
NSC-34 cells were initially incubated with 20 μg/mL of aggregated SOD1 for 30 min at 4 °C. Cells were then fixed with 4 % (w/v) paraformaldehyde (PFA) in PBS (pH 7.4) before immunodetection. In separate experiments, cells were incubated with 20 μg/mL of aggregated wtSOD1 for 60 min at 4 °C, fixed with 4 % (w/v) PFA in PBS (pH 7.4) and permeabilized, or not, with Triton x-100. SOD1 was then detected using anti-SOD1 antibodies. Cells were imaged using a Leica TCS SPII laser scanning confocal microscope (Heidelberg, Germany). In addition, quantitative analysis of SOD1 internalisation into NSC-34 cells was performed using flow cytometry using a BD LSRII (California, USA). Cells were incubated with 20 μg/mL of aggregated SOD1 for 60 min at 4 °C. Cells incubated with PBS (pH 7.4) alone acted as the control. Similar experiments were performed in the presence of the dye, Lysotracker Red as per the manufacturer’s instructions. In addition, some cells were treated with trypsin and washed extensively before being lysed after incubation with aggregated wtSOD1 for 60 min. The cell lysates were analysed by Western blotting.
Internalisation of aggregated SOD1 was measured in the presence or absence of a range of compounds that inhibit various internalisation mechanisms. NSC34 cells were pre-treated with various endocytic inhibitors including 100 μM 5-N-ethyl-N-isopropyl-amiloride (EIPA), 5 μM chlorpromazine hydrochloride (CPZ), 10 μM genistein (Gen) or 3 μM rottlerin (Rot) diluted in 1 % BSA/PBS for 30 min at 37 °C, followed by 20 μg/mL aggregated wtSOD1 for 30 min at 37 °C. Cells were then fixed and permeabilized before detection of biotinylated aggregates with SA- Alexa 488. Cells were washed once with PBS medium and analysed using a LSR II flow cytometer (BD Biosciences, San Diego, CA) (excitation 488 nm, emission collected with 515 ± 20 band-pass filters). The mean fluorescence intensity (MFI) of relative SOD1 uptake was determined using FlowJo software (Tree Star, Ashland, OR). For confocal microscopy, cells remained on glass coverslips and incubated in wells as outlined for flow cytometry. Sytox Red (5 nM) was used as a counter stain. Results are the average of at least five independent experiments.
Field emission scanning electron microscopy (FESEM)
NSC-34 cells in phenol-red serum free culture medium were plated into 12-well plates with 19 mm glass coverslips (7x104 cells/ ml/well) and starved of serum for 24 h, and treated with 20 μg/mL soluble or aggregated proteins in PBS or PBS containing 200 nM PMA for 2 h at 37 °C. Post incubation, cells were washed three times in PBS then fixed in 2.5 % glutaraldehyde/ 4 % PFA in 0.1 M phosphate buffer (pH 7.4) for 3 h at 4 °C. The cells were then washed three times in phosphate buffer and postfixed in 2 % OsO4/ water at RT for 1 h. After washing with water, the cells were dehydrated using a gradient of ethanol at 30, 50, 70, 80, 90 and 100 % (30 min per incubation) at RT. The cells were then critical point dried for 2 h using a LEICA CPD030 (Vienna, Austria) and coated with graphite-gold in a sputter coater. The samples were analysed with a JEOL 6490LV SEM (Tokyo, Japan) operated at 10 kV at a 10 mm working distance and a spot size setting of 35.
Rac1 activation assays
NSC-34 cells were treated with 20 μg/mL of soluble and aggregated G93A SOD1 for 30 min at 37 °C. The cells were washed twice with cold PBS and harvested by treatment with 0.05 % trypsin for 10 min at 37 °C. Rac1 activation was measured using a G-LISA activation kit (Kit #BK128 Cytoskeleton, Inc. (Denver, USA) as per the manufacturer’s recommendations.
Transmission electron microscopy
Negative staining was performed using substrate carbon-coated nickel grids (Proscitech Kirwan, Australia). Protein was loaded onto the grid and washed three times with milli-Q water. Subsequently, 2 % (w/v) uranyl acetate (ProsciTech Kirwan, Australia) in 0.22 μm sterile filtered milli Q water was added for 2 min to stain the proteins negatively. The grids were analysed using a JEOL 2011 TEM (Tokyo, Japan) operated at 200 kV and Images taken using a Gatan Orius digital camera (California, USA).
Pharmacological inhibitors and antibodies
Pharmacological inhibitors were prepared in either DMSO or 20 % acetonitrile/water according to the manufacturer’s recommendations and used at the indicated concentrations. EIPA, CPZ, Gen, and Rot were purchased from Sigma Aldrich. The Rac1 inhibitor W56 was purchased from Tocris Bioscience.
Specific antibodies including mouse anti-beta actin (ab8226), rabbit anti-EEA1 antibody (ab2900), Anti-LAMP1 [H4A3], anti-beta actin antibody [AC-15], anti-beta tubulin antibody, anti-neuron specific beta III tubulin were purchased from Abcam. Alexa Fluor 488 goat anti-mouse, Alexa Fluor 488 goat anti-rabbit, streptavidin Alexa Fluor 633 conjugate, streptavidin Alexa Fluor 488 conjugate, Alexa Fluor 488 donkey anti-sheep, Alexa Fluor 488 donkey anti-rabbit, SYTOX Red dead cell stain, FM® 1-43FX fixable analogue of FM® 1–43 membrane stain were purchased from Invitrogen Life Technologies. Donkey anti-sheep/goat IgG HRP conjugate and goat anti-mouse IgM + IgG + IgA (H + L) HRP conjugates were purchased from Millipore.
Sheep anti-SOD1 was purchased from Thermo Fisher Scientific. Mouse monoclonal anti-human TARDBP antibody (clone k1B8) was purchased from Abnova. Anti-BiP/GRP78 was purchased from BD Transduction Laboratories. FITC-conjugated sheep anti-mouse was purchased from Silenus. RedDot 2 was obtained from Biotium. Goat Anti-Rabbit IgG (H + L)-HRP Conjugate was obtained from Bio-Rad.
Selective permeability of cells
NSC-34 cells were incubated with 20 μg/mL of biotinylated aggregated wt and G93A SOD1 in PBS for either 60 or 120 min at 37 °C. Post incubation, cells were fixed and permeabilized with either 10 μM digitonin or 0.5 % Triton-x100 (v/v) for either 10 or 30 min at 4 °C respectively. The cells were washed three times in PBS, blocked in 5 % BSA/PBS, for subsequent detection using SA-Alexa 633. Cells were visualised using a TCS SP laser scanning confocal microscopy (Leica Microsystems, Wetzlar, Germany) using a 60x objective. The He Ne laser (633 nm) was used and emission was collected at 645 +/− 20 nm using a standard PMT. Data were acquired in Leica Application Suite (Leica Microsystems).
Cellular subfractionation
NSC-34 cells were incubated with 20 μg/mL of aggregated SOD1 in PBS for 120 min at 37 °C. Post incubation the cytosolic (CEB), membrane (MEB), nuclear (NEB) and cytoskeletal proteins (PEB) were extracted from NSC-34 cells using a Subcellular Protein Fractionation Kit for Cultured Cells (Thermo Fisher Scientific) according to the manufacturer’s instructions. Aliquots of cell extract (20 μg protein/lane) were separated under reducing conditions (5 % β-mercaptoethanol) using discontinuous TGX Stain-Free™ Precast Gels separating gels (BioRad). Proteins were then transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA) then blocked with heat denatured casein (HDC) in PBS (pH 7.4) for 1 h at 37 °C. To detect exogenously applied SOD1, sheep polyclonal anti-human SOD1 was used. To test the quality of the fractionation, rabbit anti-EEA1, anti- vimentin and mouse anti- actin antibody diluted in HDC/PBS for 1 h at 37 °C were used to probe the MEB and PEB fractions. Membranes were visualised using chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare, Little Chalfont, Bukinghamshire, UK). Images of films were collected using a GS-800 Calibrated Densitometer (Bio-Rad).
Membrane dye uptake
NSC-34 cells were treated with 20 μg/mL of soluble or aggregated wt or G93A SOD1, PBS alone, or a positive control containing 200 nM PMA in PBS for 2 h at 37 °C. The cells were then washed twice in PBS and incubated with 10 μM of FM® 1-43FX membrane stain in PBS for 7 min at 37 °C. Excess dye was removed by several washes in PBS and cells were returned to the incubator for 4 min. This procedure was repeated to give a total of 8 min of incubation in PBS. Post incubation, ice-cold PBS was added to stop endocytosis and prepare cells for fixation in 4 % (w/v) PFA/PBS (pH 7.4) for 20 min at 4 °C. Post fixation, cells were washed twice in PBS and incubated with 1x RedDot 2 for 10 min at RT.
Fluid phase uptake assays
Pinocytosis involves uptake of solutes from the extracellular medium. One well established solute is dextran. To quantify the amount of fluid phase solute uptake, NSC34 cells were treated with either 20 μg/mL of soluble and biotinylated aggregated wt and G93A SOD1, Httex146Q, α-synuclein, TDP-43, and α-lactalbumin in PBS alone or containing 200 nM PMA for 30 min at 37 °C. Prior to harvesting or fixation, cells were incubated for 15 min with 0.5 mg/ml 10 kDa 647-dextran (Invitrogen) at 37 °C. The cells were then placed on ice to stop dextran uptake and cells were washed three times with ice cold PBS and once with low pH buffer (0.1 M sodium acetate, 0.05 M NaCl, pH 5.5) for 10 min. The cells were then prepared for either flow cytometry or confocal laser scanning microscopy as described above. For flow cytometry, dextran uptake was displayed as fluorescence mean of three or more independent experiments.
Fixed cell antibody staining of iPSCs
The iPSCs were plated on matrigel-coated 8 mm coverslips at a density of 25,000 cells and cultured for 3 days before staining. Cells were fixed with 4 % (v/v) PFA at room temperature for 10 min, permeabilized with 0.5 % (v/v) TritionX-100 in phosphate buffered saline (PBS) and blocked with 5 % (w/v) bovine serum albumin (BSA) in PBS.
The iPSC colonies were stained with Oct3/4 (mouse 1:500) (Stem Cell Technologies) primary antibody overnight at 4C and anti-mouse Alexa Fluor 488 (1:1000) (Life Technologies) secondary antibody for 1 h at room temperature.
Fixed cell antibody staining of motor neurons
Cells were plated on coverslips coated with laminin (20 μg/mL) and fibronectin (10 μg/mL) at a density of 42,000 cells/cm2. Cells were fixed using 4 % (v/v) PFA at room temperature for 10 min. The cells were permeabilized with 0.5 % (v/v) Triton X-100 in PBS at room temperature for 15 min. Cells were blocked with 5 % (w/v) bovine serum albumin (BSA) in PBS at room temperature for 1 h. SMI32 primary antibody (Abcam) was diluted 1:800 in PBS 5 % BSA and incubated at 4 °C overnight. Secondary antibodies, Alexa Fluor 488 anti-sheep IgG antibody (1:1000 in PBS 5 % BSA) was incubated with the cells for 1 h at room temperature. Images of stained cells were taken on a Leica DMI6000B confocal microscope and acquired using the LAS AF 2.3.5 software.
Quantitative RT-PCR
RNA was extracted and purified from differentiated cell using the ISOLATE II RNA Mini Kit (Bioline, USA), as per manufacturer’s instructions. The purified RNA was quantified using a Nanodrop 2000C (Thermo Fisher Scientific, USA).
RNA was reverse transcribed into complementary DNA (cDNA) for subsequent analysis. Reagents for cDNA preparation were obtained from Promega (USA). Five μg of purified RNA was annealed to random primers (0.75 μg) and oligo dT primers (0.75 μg) by incubating at 65 °C for 4 min, followed by 1 min incubation on ice. For reverse transcription, Moloney-murine leukaemia virus reverse transcriptase (M-MLV RTase) (150 U), 96 nmol dNTPs, RNasin (60 U) and 1x MMLV RTase Buffer were added to the reaction mixture and then incubated at 37 °C for 100 min.
The primers for qRT-PCR were obtained from Sigma Aldrich (USA) (unless stated otherwise) and had the following sequences:
-
acetylcholinesterase (AChE)
-
forward: 5’-GGAACCGCTTCCTCCCCAAATTG-3’,
-
reverse: 5’-TGCTGTAGTGGTCGAACTGGTTCTTC-3’; Homeobox 9 (MNX1)
-
forward: 5’-GTTCAAGCTCAACAAGTACC-3’,
-
reverse: 5’-GGTTCTGGAACCAAATCTTC-3’; GFAP
-
forward: 5’-CTGGATCTGGAGAGGAAGATTGAGTCG-3’,
-
reverse: 5’-CTCATACTGCGTGCGGATCTCTTTCA-3’; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) forward: 5’-GAGCACAAGAGGAAGAGAGAGACCC-3’, reverse: 5’-GTTGAGCACAGGGTACTTTATTGATGGTACATG-3’. The final qRT-PCR reaction consisted of 10 μL of SYBR Select Master Mix, 800 nM of each forward and reverse primer, 2 μL of cDNA in a final reaction volume of 20 μL. Each reaction was run in duplicate and a negative control (water) and no reverse transcription (RNA) control was included as well as a positive control using cDNA of human putamen. The amplification consisted of 40 cycles, of 95 °C for 15 s (activation step), 58 °C for 15 s (annealing step) and 72 °C for 1 min. A melting curve analysis was conducted to confirm the presence of the appropriate amplified target. The acquired data was normalized against quantitative expression levels of the housekeeping gene GAPDH and analyzed using the comparative threshold cycle method.
Preparation of giant unilamellar vesicles
The rapid evaporation method was used to prepare giant unilamellar vesicles for confocal microscopy as described in [
36]. Briefly, soy L-α-phosphatidylcholine (Avanti Polar Lipids Inc) was dissolved in CHCl
3:MeOH (2:1) to give a phospholipid concentration of 5 mM. Liposome buffer (50 mM HEPES, 107 mM NaCl, 1 mM EDTA, 0.1 M sucrose, pH 7.4, 2.5 mL) was then added to the lipid/solvent solution in a 50 mL round bottom flask and the two phases mixed by vigorous pipetting. The organic solvent was removed by rotary evaporator under reduced pressure (final pressure 44 mbar) for 5 min at 35 °C. The resulting liposome suspension was stored overnight at 4 °C prior to confocal microscopy studies.
Competing interests
N.R.C. is the founder, Chief Scientific Officer, and Chairman of Amorfix Life Sciences.
Authors’ contributions
JJY conceptualized, designed and supervised the experiments, analyzed the data and wrote the paper. RZ designed and performed experiments, analyzed data and wrote the paper. ES, JP, LC, DD, MB performed experiments and analyzed data. GG, DMH, HE, CMD, LO contributed resources and to writing/editing the manuscript. MRW and NRC contributed to experimental design and writing of the manuscript. All authors read and approved the final manuscript.